{
    "id": "0a07ca84-9ad7-4c60-be47-de10955b4098",
    "indications": {
        "text": "lyrica indicated : \u2022management neuropathic pain associated diabetic peripheral neuropathy \u2022management postherpetic neuralgia \u2022adjunctive therapy treatment partial\u2011onset seizures patients 1 month age older \u2022management fibromyalgia \u2022management neuropathic pain associated spinal cord injury",
        "doid_entities": [
            {
                "text": "peripheral neuropathy (DOID:574)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_574"
            },
            {
                "text": "neuropathy (DOID:870)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_870"
            },
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adult , begin dosing 150 mg/day . partial\u2011onset seizure dosing pediatric patients 1 month age older , refer section 2.4 . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) \u2022 dosing recommendations : indication dosing regimen maximum dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week . phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . adjunctive therapy partial\u2011onset seizures pediatric adult patients weighing 30 kg ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day . adjunctive therapy partial\u2011onset seizures pediatric patients weighing less 30 kg ( 2.4 ) 1 month less 4 years : 3 divided doses per day 4 years older : 2 3 divided doses per day 14 mg/kg/day . fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day . neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . \u2022 dose adjusted adult patients reduced renal function . ( 2.7 )",
        "doid_entities": [
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "25 mg capsules : white , hard-gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 25 \u201d body ; available : bottles 90 : ndc 58151-236-77 50 mg capsules : white , hard-gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 50 \u201d ink band body , available : bottles 90 : ndc 58151-237-77 unit-dose blister packages 100 : ndc 58151-237-88 75 mg capsules : white/orange hard gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 75 \u201d body ; available : bottles 90 : ndc 58151-238-77 unit-dose blister packages 100 : ndc 58151-238-88 100 mg capsules : orange , hard-gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 100 \u201d body , available : bottles 90 : ndc 58151-239-77 unit-dose blister packages 100 : ndc 58151-239-88 150 mg capsules : white hard gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 150 \u201d body , available : bottles 90 : ndc 58151-240-77 unit-dose blister packages 100 : ndc 58151-240-88 200 mg capsules : light orange hard gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 200 \u201d body , available : bottles 90 : ndc 58151-241-77 225 mg capsules : white/light orange hard gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 225 \u201d body ; available : bottles 90 : ndc 58151-243-77 300 mg capsules : white/orange hard gelatin capsule printed black ink \u201c vtrs \u201d cap , \u201c pgn \u201d \u201c 300 \u201d body , available : bottles 90 : ndc 58151-242-77 20 mg/ml oral solution : 16 fluid ounce white high density polyethylene ( hdpe ) bottle polyethylene-lined closure : 16 fluid ounce bottle ndc 58151-244-35 storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) ( usp controlled room temperature ) .",
    "adverseReactions": "lyrica contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "organization": "Viatris Specialty LLC",
    "name": "Lyrica",
    "effectiveTime": "20250415",
    "indications_original": "LYRICA is indicated for:\n                  \n                     \n                        \u2022Management of neuropathic pain associated with diabetic peripheral neuropathy\n                     \n                        \u2022Management of postherpetic neuralgia\n                     \n                        \u2022Adjunctive therapy for the treatment of partial\u2011onset seizures in patients 1\u00a0month of age and older \n                     \n                        \u2022Management of fibromyalgia\n                     \n                        \u2022Management of neuropathic pain associated with spinal cord injury",
    "contraindications_original": "\u2022 For adult indications, begin dosing at 150 mg/day. For partial\u2011onset seizure dosing in pediatric patients 1\u00a0month of age and older, refer to section 2.4. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) \u2022 Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1\u00a0week. PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1\u00a0week. Maximum dose of 600 mg/day. Adjunctive Therapy for Partial\u2011Onset Seizures in Pediatric and Adult Patients Weighing 30\u00a0kg or More ( 2.4 ) 2 or 3 divided doses per day Maximum dose of 600\u00a0mg/day. Adjunctive Therapy for Partial\u2011Onset Seizures in Pediatric Patients Weighing Less than 30\u00a0kg ( 2.4 ) 1 month to less than 4\u00a0years: 3 divided doses per day 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day. Fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1\u00a0week. Maximum dose of 450\u00a0mg/day. Neuropathic Pain Associated with Spinal Cord Injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1\u00a0week. Maximum dose of 600 mg/day. \u2022 Dose should be adjusted in adult patients with reduced renal function. ( 2.7 )",
    "warningsAndPrecautions_original": "25 mg capsules:\n                  \n                  White, hard-gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c25\u201d on the body; available in:\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-236-77\n                  \n                     50 mg capsules:\n                  \n                  White, hard-gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c50\u201d and an ink band on the body, available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-237-77\n                  Unit-Dose Blister Packages of 100: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-237-88\n                  \n                     75 mg capsules:\n                  \n                  White/orange hard gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c75\u201d on the body; available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-238-77\n                  Unit-Dose Blister Packages of 100: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-238-88\n                  \n                     100 mg capsules:\n                  \n                  Orange, hard-gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c100\u201d on the body, available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-239-77\n                  Unit-Dose Blister Packages of 100: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-239-88\n                  \n                     150 mg capsules:\n                  \n                  White hard gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c150\u201d on the body, available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-240-77\n                  Unit-Dose Blister Packages of 100: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-240-88\n                  \n                     200 mg capsules:\n                  \n                  Light orange hard gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c200\u201d on the body, available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-241-77\n                  \n                     225 mg capsules:\n                  \n                  White/light orange hard gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c225\u201d on the body; available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-243-77\n                  \n                     300 mg capsules:\n                  \n                  White/orange hard gelatin capsule printed with black ink \u201cVTRS\u201d on the cap, \u201cPGN\u201d over \u201c300\u201d on the body, available in:\n                  Bottles of 90: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-242-77\n                  \n                     20 mg/mL oral solution:\n                  \n                  16 fluid ounce white high density polyethylene (HDPE) bottle with a polyethylene-lined closure: \n                  16 fluid ounce bottle\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 58151-244-35\n                  Storage and Handling\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) (see USP Controlled Room Temperature).",
    "adverseReactions_original": "LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "Lyrica",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        }
    ]
}